ClinicalTrials.gg

Program

ubrogepant

Also written as “Ubrogepant”, “MK-1602” and “Ubrogepant 100 mg”.

Its studies are mostly in Migraine Disorders, led by AbbVie.

Furthest: phase 4, since Feb 22, 202213 company-led studies, 3 open or runningNext primary completion: May 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie133 open or runningphase 4since Feb 22, 2022May 16, 2012May 2027phase 3 · NCT05125302

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 16, 2012First study: phase 2 study in Migraine DisordersFirst studyNCT01613248 · 834 enrolled
  2. Aug 2, 2012Phase 2 study in Migraine DisordersNCT01657370 · 195 enrolled
  3. Jul 7, 2016Phase 3 study in Migraine DisordersNCT02828020 · 1,672 enrolled · United States
  4. Aug 12, 20162 phase 3 studies in Migraine DisordersNCT02867709, NCT02873221
  5. Sep 26, 2019Phase 1 study in Migraine DisordersNCT04179474 · 40 enrolled · United States
  6. Jul 27, 2020Phase 3 study in Migraine DisordersNCT04492020 · 518 enrolled · United States
  7. Mar 24, 2021Phase 1 study in Migraine DisordersNCT04818515 · 26 enrolled · United States
  8. Nov 8, 20212 phase 3 studies in Migraine DisordersNCT05125302, NCT05127954
  9. Feb 22, 2022Phase 4 study in Episodic MigraineNCT05264129 · 263 enrolled · United States
  10. May 13, 2024Phase 3 study in Migraine DisordersNCT06417775 · 496 enrolled · United States, Puerto Rico
  11. Jun 26, 2026Phase 1 study in Healthy VolunteerNCT07680686 · 52 enrolled · United States

Ahead

  1. May 2027Primary completion: phase 3 study in Migraine DisordersNCT05125302
  2. Nov 2027Primary completion: phase 3 study in Migraine DisordersNCT06417775
  3. Jan 2028Primary completion: phase 3 study in Migraine DisordersNCT05127954

TargetBeta

“An orally bioavailable calcitonin gene-related peptide (CGRP) receptor antagonist that can be used in the acute treatment of migraines”NCIt, by rule
“Calcitonin gene-related peptide type 1 receptor antagonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
atogepantruleAbbViephase 419
zavegepantrulePfizerphase 313

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07680686Healthy Volunteer · United States1CompletedOct 16, 202652
NCT06417775Migraine Disorders · United States, Puerto Rico3Active, not recruitingNov 2027496
NCT05264129Episodic Migraine · United States4CompletedApr 4, 2023263
NCT05127954Migraine Disorders · United States, Puerto Rico3By invitationJan 20281,200
NCT05125302Migraine Disorders · United States, Puerto Rico3RecruitingMay 20271,059
NCT04818515Migraine Disorders · United States1CompletedJun 18, 202126
NCT04492020Migraine Disorders · United States3CompletedApr 19, 2022518
NCT04179474Migraine Disorders · United States1CompletedDec 23, 201940
NCT02873221Migraine Disorders · United States3CompletedAug 2, 20181,254
NCT02867709Migraine Disorders · United States3CompletedJan 25, 20181,686
NCT02828020Migraine Disorders · United States3CompletedDec 13, 20171,672
NCT01657370Migraine Disorders2CompletedNov 2012195
NCT01613248Migraine Disorders2CompletedDec 1, 2012834

How it is read

Names in the registry

  • “Ubrogepant”, 11 entries
  • “MK-1602”, 2 entries
  • “Ubrogepant 100 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.